Mutational status may supersede tumor size in predicting the presence of aggressive pathologic features in well differentiated thyroid cancer

[1]  A. Theodoropoulou,et al.  The 2017 bethesda system for reporting thyroid cytopathology: the experience of a tertiary center , 2023, Endocrine Abstracts.

[2]  M. Hier,et al.  Association of Bethesda category and molecular mutation in patients undergoing thyroidectomy , 2021, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.

[3]  R. Seethala,et al.  Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: A matched case‐control study , 2021, Cancer.

[4]  A. Leung,et al.  Correlation of ThyroSeq Results with Surgical Histopathology in Cytologically Indeterminate Thyroid Nodules , 2020, Endocrine Pathology.

[5]  S. Al-Salam,et al.  BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates , 2020, PloS one.

[6]  M. Hier,et al.  Molecular mutations as a possible factor for determining extent of thyroid surgery , 2019, Journal of Otolaryngology - Head & Neck Surgery.

[7]  H. Cramer,et al.  Risk of malignancy and neoplasia predicted by three molecular testing platforms in indeterminate thyroid nodules on fine‐needle aspiration , 2019, Diagnostic cytopathology.

[8]  R. Ling,et al.  Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma , 2019, Endocrine connections.

[9]  Yan Shen,et al.  Comparison of Different Risk-Stratification Systems for the Diagnosis of Benign and Malignant Thyroid Nodules , 2019, Front. Oncol..

[10]  N. Qu,et al.  Effects of tumor size on prognosis in differentiated thyroid carcinoma smaller than 2 cm , 2019, Oncology letters.

[11]  D. Roshan,et al.  The Prognostic Impact of Tumor Size in Papillary Thyroid Carcinoma is Modified by Age. , 2018, Thyroid : official journal of the American Thyroid Association.

[12]  N. Inoshita,et al.  The 2017 WHO classification of pituitary adenoma: overview and comments , 2018, Brain Tumor Pathology.

[13]  K. Roy Choudhury,et al.  Effect of Tumor Size on Risk of Metastatic Disease and Survival for Thyroid Cancer: Implications for Biopsy Guidelines. , 2018, Thyroid : official journal of the American Thyroid Association.

[14]  Publisher's Note , 2018, Anaesthesia.

[15]  E. Cibas,et al.  The 2017 Bethesda System for Reporting Thyroid Cytopathology. , 2017, Journal of the American Society of Cytopathology.

[16]  E. Cibas,et al.  The 2017 Bethesda System for Reporting Thyroid Cytopathology. , 2017, Thyroid : official journal of the American Thyroid Association.

[17]  M. Lopes,et al.  The 2017 World Health Organization classification of tumors of the pituitary gland: a summary , 2017, Acta Neuropathologica.

[18]  A. Gawande,et al.  Clinical, Sonographic, and Pathological Characteristics of RAS-Positive Versus BRAF-Positive Thyroid Carcinoma. , 2016, The Journal of clinical endocrinology and metabolism.

[19]  K. Bible,et al.  Evolving molecularly targeted therapies for advanced-stage thyroid cancers , 2016, Nature Reviews Clinical Oncology.

[20]  Sun Wook Cho,et al.  Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients , 2016, Cancer.

[21]  Yong Joon Suh,et al.  BRAF(V600E) Is Correlated with Recurrence of Papillary Thyroid Microcarcinoma: A Systematic Review, Multi-Institutional Primary Data Analysis, and Meta-Analysis. , 2016, Thyroid : official journal of the American Thyroid Association.

[22]  C. Chen,et al.  Association between BRAF and RAS mutations, and RET rearrangements and the clinical features of papillary thyroid cancer. , 2015, International journal of clinical and experimental pathology.

[23]  S. Haddar,et al.  The Thyroid Imaging Reporting and Data System (TIRADS) for ultrasound of the thyroid : a pratical approach , 2015 .

[24]  Steven J. M. Jones,et al.  Integrated Genomic Characterization of Papillary Thyroid Carcinoma , 2014, Cell.

[25]  K. Robinson,et al.  Increases in thyroid nodule fine-needle aspirations, operations, and diagnoses of thyroid cancer in the United States. , 2013, Surgery.

[26]  James H. Doroshow,et al.  Abeloff's Clinical Oncology , 2013 .

[27]  G. Braunstein,et al.  Comparison with published systems of a new staging system for papillary and follicular thyroid carcinoma. , 2013, Thyroid : official journal of the American Thyroid Association.

[28]  P. Ladenson,et al.  Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. , 2013, JAMA.

[29]  M. Xing,et al.  Molecular pathogenesis and mechanisms of thyroid cancer , 2013, Nature Reviews Cancer.

[30]  A. Pinchera,et al.  The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. , 2012, The Journal of clinical endocrinology and metabolism.

[31]  M. Zeiger,et al.  BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. , 2012, The Journal of clinical endocrinology and metabolism.

[32]  M. Tublin,et al.  Suspicious ultrasound characteristics predict BRAF V600E-positive papillary thyroid carcinoma. , 2012, Thyroid : official journal of the American Thyroid Association.

[33]  F. Pacini,et al.  Approach to and treatment of differentiated thyroid carcinoma. , 2012, The Medical clinics of North America.

[34]  M. Hier,et al.  McGill Thyroid Nodule Score (MTNS): "rating the risk," a novel predictive scheme for cancer risk determination. , 2011, Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale.

[35]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[36]  S. Mandel,et al.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[37]  Z. Jehan,et al.  Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. , 2008, The Journal of clinical endocrinology and metabolism.

[38]  Ju-Han Lee,et al.  Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid , 2007, Cancer.

[39]  A. Toniato,et al.  Papillary Thyroid Carcinoma: 35-Year Outcome and Prognostic Factors in 1858 Patients , 2007, Clinical nuclear medicine.

[40]  H. Holzhausen,et al.  The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma , 2005, Cancer.

[41]  J. Shah,et al.  Risk group stratification and prognostic factors in papillary carcinoma of thyroid , 1996, Annals of Surgical Oncology.

[42]  S. Jhiang,et al.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. , 1994, The American journal of medicine.

[43]  C. Begg,et al.  Prognostic factors in differentiated carcinoma of the thyroid gland. , 1992, American journal of surgery.

[44]  G. van Melle,et al.  Prognostic factors in papillary carcinoma of the thyroid , 1991, Cancer.

[45]  S. McKinney,et al.  Papillary and follicular thyroid cancer. Prognostic factors in 1,578 patients. , 1987, The American journal of medicine.

[46]  Kaliszewski,et al.  American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer : The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer , 2017 .

[47]  R. Seethala,et al.  Preoperative detection of RAS mutation may guide extent of thyroidectomy , 2017, Surgery.

[48]  A. Sanabria,et al.  The Bethesda system for reporting thyroid cytopathology in Colombia: Correlation with histopathological diagnoses in oncology and non-oncology institutions , 2015, Journal of cytology.

[49]  [Carcinoma]. , 1955, Die Medizinische.